Table 3.
Comparison of baseline characteristics, treatment, and outcome by the degree of microhematuria (n = 77)
| Microhematuria | Low-degree, 0–1 (n = 16) | High-degree, 2–3 (n = 61) | Significance |
|---|---|---|---|
| Age at biopsy, years | 37.6±14.8 | 37.1±13.4 | p = 0.910 |
| Sex (male:female as %) | 56:44 | 80:20 | p = 0.047 |
| Follow-up time (median as months) | 132.8±52.9 | 128.3±57.0 | p = 0.631 |
| eGFR, mL/min | 86.9±27.0 | 74.3±29.2 | p = 0.121 |
| eGFR-slope 5 years past biopsy | 0.05±3.75 | –2.20±5.18 | p = 0.103 |
| MAP, mm Hg | 96.6±11.7 | 97.7±10.4 | p = 0.734 |
| TA-MAP 5 years past biopsy, mm Hg | 94.0±7.4 | 93.5±6.8 | p = 0.817 |
| Albuminuria, g/day | 1.12±1.54 | 1.75±2.11 | p = 0.132 |
| TA-Albuminuria 5 years past biopsy, g/day | 0.55±0.69 | 0.97±1.54 | p = 0.145 |
| BMI (n = 76) | 26.2±5.1 | 26.1±4.7 (n = 60) | p = 0.929 |
| Treatment with ACEi or ARB at the time of biopsy, n (%) | 8 (50.0) | 24 (39.3) | p = 0.441 |
| Treatment with ACEi or ARB at the time of at least one follow-up, n (%) | 13 (81.3) | 52 (85.2) | p = 0.695 |
| Immunosuppression within 1 year of biopsy, n (%) | 2 (12.5) | 13 (23.0) | p = 0.428 |
| Immunosuppression at any point during or before the study, n (%) | 5 (31.3) | 15 (26.2) | p = 0.589 |
| Predicted 5-year risk, % | 5.68±10.1 | 8.84±10.6 | p = 0.03 |
| Reached the outcome of –50% eGFR or ESRD, n (%) | 1 (6.3) | 16 (26.2) | p = 0.109 |
| M | 5 (31.3) | 18 (29.5) | p = 0.892 |
| E | 3 (18.8) | 17 (27.9) | p = 0.459 |
| S | 12 (75.0) | 52 (85.2) | p = 0.330 |
| T (2:1:0 as %) | 0:4:12 (0:25:75) | 9:19:33 (14.8:31.1:54.1) | p = 0.177 |
Continuous variables are reported as mean ± standard deviation (SD) unless otherwise stated. When information on a variable is missing from patients, the number in the parenthesis states the number of patients with a valid measurement of the variable in question. Significant p values are highlighted in bold.